WEBULL
WebtradeDownload

BillionToOne (BLLN) Stock Looks Reasonable On Cash Flow Estimates

Simply Wall St · 3d ago

BillionToOne has logged a solid share price run this year, and the stock closed at US$114.42 most recently. The question for anyone looking at BillionToOne now is whether that price still lines up with what its cash flows can reasonably support.

  • The stock is up 28.1% year to date, which puts the focus squarely on whether cash generation can keep pace with the share price move.
  • The business model now faces a simple test: whether expected cash inflows from its existing pipeline and growth plans can comfortably fund operations without putting persistent strain on the balance sheet.
  • If you'd rather focus on sales, this one's for you. See why BillionToOne's 13.6x P/S tells a different valuation story.

The issue now is whether BillionToOne's current market value is justified by the cash flows implied by a Discounted Cash Flow (DCF) view of the business.

If you are weighing BillionToOne against other opportunities that also hinge on cash generation and valuation, it can help to compare it with a wider set of 30 high quality undervalued stocks

Is BillionToOne a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here is based on what BillionToOne can produce in free cash over time. On the latest twelve month numbers, the business generated about $30.5 million in free cash flow, which is the starting point for the 2 Stage Free Cash Flow to Equity approach.

Analysts and model estimates project growing free cash flows over the coming decade, with the profile moving from current levels toward materially higher figures by 2030 and beyond. That growth path, when discounted back using the DCF framework, leads to an estimated intrinsic value that is substantially above the current share price of US$114.42. For readers comparing valuation against price, the key takeaway is that the cash flow projections used in this model imply more value than the market is currently assigning to BillionToOne stock. Find out what BillionToOne could be worth using our Discounted Cash Flow (DCF) estimate.

The BillionToOne Narrative: What Would Justify Today's Price?

For anyone trying to link BillionToOne's DCF puzzle to real world expectations, Simply Wall St Narratives sit on the Community page and spell out the kind of growth, margins and earnings path that would need to hold for the stock to end up worth meaningfully more or less than today’s price. Rather than relying on a single multiple or model output, each narrative lays out the key assumptions behind its fair value view so you can compare those to actual results as they are reported.

BillionToOne draws two very different read throughs from the community, with one side focusing on reimbursement and product traction and the other on execution and competitive risk.

Bull case: 6% undervalued

"Growing adoption of noninvasive prenatal testing and broader carrier screening, supported by UNITY publications and an exclusive Johnson & Johnson companion diagnostic agreement, can support higher test volumes and ASPs..."

Discover why this Narrative puts BillionToOne at 6% undervalued.

Bear case: 27% overvalued

"Liquid biopsy and prenatal testing are crowded areas, and competitors are launching fetal risk assessment and MRD products that target the same long term opportunities, which could slow UNITY and Northstar volume growth and limit the ability to sustain current revenue trends and ASP levels..."

Explore why this Narrative puts BillionToOne at 27% overvalued.

The BillionToOne story also hinges on who is in charge

Price and cash flow only tell part of the story, because the people steering BillionToOne and the way their pay is structured can tilt long term outcomes in very different directions. See who runs BillionToOne and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.